Cabozantinib in combination with nivolumab for previously untreated advanced renal cell cancer

Published on 31 Aug 2022
Last Updated on 02 Jan 2024

Guidance Recommendations

The Ministry of Health’s Drug Advisory Committee has not recommended cabozantinib in combination with nivolumab for inclusion on the MOH List of Subsidised Drugs for previously untreated advanced renal cell cancer in view of unfavourable cost-effectiveness compared with alternative treatments.

Clinical indications, subsidy class and MediShield Life claim limits for both drugs are provided in the Annex.

Cabozantinib with nivolumab for previously untreated advanced RCC (Updated 1 Aug 2023) [PDF, 132 KB]

PES Treatments for advanced renal cell carcinoma (Updated 2 Jan 2024) [PDF, 111 KB]